Philip N Hawkins

List of Publications by Year
in descending order

107 papers	13,984 citations	57758 44 h-index	38395 95 g-index
111 all docs	111 docs citations	111 times ranked	8965 citing authors

#	Article	IF	Citations
1	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation, 2016, 133, 2404-2412.	1.6	1,335
2	Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. American Journal of Hematology, 2005, 79, 319-328.	4.1	1,179
3	Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature, 1997, 385, 787-793.	27.8	1,061
4	New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes. Journal of Clinical Oncology, 2012, 30, 4541-4549.	1.6	735
5	Spectrum of clinical features in Muckleâ€Wells syndrome and response to anakinra. Arthritis and Rheumatism, 2004, 50, 607-612.	6.7	731
6	Systemic amyloidosis. Lancet, The, 2016, 387, 2641-2654.	13.7	703
7	Misdiagnosis of Hereditary Amyloidosis as AL (Primary) Amyloidosis. New England Journal of Medicine, 2002, 346, 1786-1791.	27.0	621
8	Evaluation of Systemic Amyloidosis by Scintigraphy with¹²³I-Labeled Serum Amyloid P Component. New England Journal of Medicine, 1990, 323, 508-513.	27.0	497
9	Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation, 2015, 132, 1570-1579.	1.6	442
10	EULAR recommendations for the management of familial Mediterranean fever. Annals of the Rheumatic Diseases, 2016, 75, 644-651.	0.9	393
11	A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood, 2013, 121, 3420-3427.	1.4	385
12	Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAPâ€met³⁰). Clinical Genetics, 1991, 40, 242-246.	2.0	350
13	Systemic immunoglobulin light chain amyloidosis. Nature Reviews Disease Primers, 2018, 4, 38.	30.5	350
14	Native T1 Mapping in Transthyretin Amyloidosis. JACC: Cardiovascular Imaging, 2014, 7, 157-165.	5.3	339
15	A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood, 2015, 126, 612-615.	1.4	334
16	T1 mapping and survival in systemic light-chain amyloidosis. European Heart Journal, 2015, 36, 244-251.	2.2	310
17	Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. New England Journal of Medicine, 2015, 373, 1106-1114.	27.0	304
18	Magnetic Resonance in TransthyretinÂCardiac Amyloidosis. Journal of the American College of Cardiology, 2017, 70, 466-477.	2.8	290

#	Article	IF	Citations
19	CMR-Based Differentiation of AL and ATTR Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2014, 7, 133-142.	5.3	242
20	Online Registry for Mutations in Hereditary Amyloidosis Including Nomenclature Recommendations. Human Mutation, 2014, 35, E2403-E2412.	2.5	220
21	Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. British Journal of Haematology, 2000, 110, 454-460.	2.5	192
22	Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. European Heart Journal Cardiovascular Imaging, 2014, 15, 1289-1298.	1.2	184
23	Native T1 and Extracellular Volume inÂTransthyretin Amyloidosis. JACC: Cardiovascular Imaging, 2019, 12, 810-819.	5.3	172
24	AMYLOIDOSIS: A REVIEW OF RECENT DIAGNOSTIC AND THERAPEUTIC DEVELOPMENTS. British Journal of Haematology, 1997, 99, 245-256.	2.5	166
25	Automated Pixel-Wise Quantitative Myocardial Perfusion Mapping by CMRÂtoÂDetect Obstructive Coronary Artery Disease and Coronary Microvascular Dysfunction. JACC: Cardiovascular Imaging, 2019, 12, 1958-1969.	5.3	140
26	Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Current Opinion in Nephrology and Hypertension, 2002, 11, 649-655.	2.0	132
27	A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood, 2019, 134, 2271-2280.	1.4	130
28	Diagnostic Performance of 123I-Labeled Serum Amyloid P Component Scintigraphy in Patients with Amyloidosis. American Journal of Medicine, 2006, 119, 355.e15-355.e24.	1.5	129
29	Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica, 2014, 99, 1479-1485.	3.5	118
30	Cardiac Structural and Functional Consequences of Amyloid Deposition byÂCardiac Magnetic Resonance andÂEchocardiography and TheirÂPrognosticÂRoles. JACC: Cardiovascular Imaging, 2019, 12, 823-833.	5.3	113
31	Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. European Heart Journal, 2020, 41, 1439-1447.	2.2	108
32	Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study. Lancet Haematology,the, 2015, 2, e241-e250.	4.6	105
33	SAA₁alleles as risk factors in reactive systemic AA amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1998, 5, 262-265.	3.0	104
34	Systemic amyloidosis. Current Opinion in Pharmacology, 2006, 6, 214-220.	3.5	102
35	Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. British Journal of Haematology, 2006, 134, 417-425.	2.5	84
36	International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatology, 2017, 56, 2102-2108.	1.9	84

#	Article	IF	Citations
37	Diagnostic imaging of cardiac amyloidosis. Nature Reviews Cardiology, 2020, 17, 413-426.	13.7	84
38	Studies with Radiolabelled Serum Amyloid P Component Provide Evidence for Turnover and Regression of Amyloid Deposits In Vivo. Clinical Science, 1994, 87, 289-295.	4.3	75
39	Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 709-713.	6.4	68
40	European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin Mâ€“Related Light Chain Amyloidosis. Journal of Clinical Oncology, 2016, 34, 2037-2045.	1.6	60
41	Allogeneic bone marrow transplantation for systemic AL amyloidosis. British Journal of Haematology, 1998, 100, 226-228.	2.5	51
42	Measurement of Tissue Interstitial Volume in Healthy Patients and Those with Amyloidosis with Equilibrium Contrast-enhanced MR Imaging. Radiology, 2013, 268, 858-864.	7.3	49
43	Autosomal dominant familial Mediterranean fever in Northern European Caucasians associated with deletion of p.M694 residueâ€”a case series and genetic exploration. Rheumatology, 2017, 56, 209-213.	1.9	49
44	An autosomal dominant periodic fever associated with AA amyloidosis in a North Indian family maps to distal chromosome 1q. Arthritis and Rheumatism, 2000, 43, 2034-2040.	6.7	48
45	Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis. European Heart Journal, 2022, 43, 333-341.	2.2	45
46	Assessment of Multivessel Coronary Artery Disease Using Cardiovascular Magnetic Resonance Pixelwise Quantitative Perfusion Mapping. JACC: Cardiovascular Imaging, 2020, 13, 2546-2557.	5.3	30
47	A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis. Journal of Cardiology Cases, 2011, 4, e93-e97.	0.5	29
48	Hereditary systemic amyloidosis with renal involvement. Journal of Nephrology, 2003, 16, 443-8.	2.0	29
49	Acute changes in cardiac structural and tissue characterisation parameters following haemodialysis measured using cardiovascular magnetic resonance. Scientific Reports, 2019, 9, 1388.	3.3	27
50	Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. European Heart Journal, 2022, 43, 2622-2632.	2.2	27
51	99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis. European Heart Journal Cardiovascular Imaging, 2021, 22, 1304-1311.	1.2	26
52	ALchemy - A Large Prospective â€˜Real World' Study of Chemotherapy in AL Amyloidosis. Blood, 2011, 118, 992-992.	1.4	26
53	Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. European Journal of Heart Failure, 2022, 24, 1700-1712.	7.1	26
54	Emerging treatments for amyloidosis. Kidney International, 2015, 87, 516-526.	5.2	25

#	Article	IF	Citations
55	A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis. Blood, 2010, 116, 988-988.	1.4	25
56	Two types of amyloid in a single heart. Blood, 2014, 124, 3025-3027.	1.4	24
57	Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities. Journal of the American Heart Association, 2019, 8, e012097.	3.7	21
58	Cardiac Magnetic Resonanceâ€“Derived Extracellular Volume Mapping for the Quantification of Hepatic and Splenic Amyloid. Circulation: Cardiovascular Imaging, 2021, 14, CIRCIMAGING121012506.	2.6	19
59	Validation of the Criteria of Response to Treatment In AL Amyloidosis.. Blood, 2010, 116, 1364-1364.	1.4	19
60	Quantitative cardiovascular magnetic resonance myocardial perfusion mapping to assess hyperaemic response to adenosine stress. European Heart Journal Cardiovascular Imaging, 2021, 22, 273-281.	1.2	15
61	Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting. Haematologica, 2014, 99, e260-e263.	3.5	14
62	Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance. Leukemia, 2020, 34, 1187-1191.	7.2	13
63	Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis â€“ Results From the UK Amyloidosis Treatment Trial.. Blood, 2009, 114, 2869-2869.	1.4	13
64	001â€…Multiparametric mapping to understand pathophysiology in cardiac amyloidosis. Heart, 2017, 103, A1-A2.	2.9	12
65	Efficacy and Safety of Bortezomib in Systemic AL Amyloidosis - A Preliminary Report.. Blood, 2006, 108, 129-129.	1.4	11
66	TRAP1 chaperone protein mutations and autoinflammation. Life Science Alliance, 2020, 3, e201900376.	2.8	9
67	Comparison of Free Light Chain Assays. American Journal of Clinical Pathology, 2016, 146, 78-85.	0.7	8
68	Apolipoprotein E4 genotype is not a risk factor for systemic AA amyloidosis or familial amyloid polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1995, 2, 163-166.	3.0	7
69	Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts. Haematologica, 2017, 102, e411-e414.	3.5	7
70	Intermediate Dose Intravenous Melphalan and Dexamethasone Treatment in 144 Patients with Systemic AL Amyloidosis.. Blood, 2004, 104, 755-755.	1.4	7
71	Role of NT-ProBNP to Assess the Adequacy of Treatment Response in AL Amyloidosis.. Blood, 2008, 112, 1689-1689.	1.4	7
72	Role of ^{99m}Tcâ€DPD scintigraphy in imaging extraâ€cardiac light chain (AL) amyloidosis. British Journal of Haematology, 2018, 183, 506-509.	2.5	6

#	Article	IF	Citations
73	Two types of systemic amyloidosis in a single patient. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 275-276.	3.0	6
74	Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis. Blood, 2008, 112, 869-869.	1.4	6
75	A New Staging System for AL Amyloidosis Incorporating Serum Free Light Chains, cardiac Troponin-T and NT-ProBNP.. Blood, 2009, 114, 2796-2796.	1.4	6
76	In AL Amyloidosis, Both Oral Melphalan and Dexamethasone (Mel-Dex) and Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Have Similar Efficacy as Upfront Treatment.. Blood, 2009, 114, 745-745.	1.4	6
77	High prevalence of recurrent nocturnal desaturations in systemic AL amyloidosis: a cross-sectional pilot study. Sleep Medicine, 2017, 32, 191-197.	1.6	5
78	Search for AL amyloidosis risk factors using Mendelian randomization. Blood Advances, 2021, 5, 2725-2731.	5.2	5
79	European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease. Blood, 2011, 118, 995-995.	1.4	5
80	Six-minute walk test (6MWT) in AL amyloidosis â€“ baseline and 12-month follow-up after chemotherapy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 62-63.	3.0	4
81	Recognising and understanding cryopyrin-associated periodic syndrome in adults. British Journal of Nursing, 2019, 28, 1180-1186.	0.7	4
82	Transient Post Chemotherapy Rise in NT Pro-BNP in AL Amyloidosis : Implications for Organ Response Assessment.. Blood, 2009, 114, 1791-1791.	1.4	4
83	A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 72-73.	3.0	3
84	The UK National Amyloidosis Centre. European Heart Journal, 2019, 40, 1661-1664.	2.2	3
85	Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) for the Treatment of Systemic AL Amyloidosis: Long Term Outcomes among 202 Patients.. Blood, 2008, 112, 1733-1733.	1.4	3
86	Acute Hepatitis in a Child Heterozygous for the I259V MEFV Gene Variant. Prague Medical Report, 2014, 115, 128-133.	0.8	3
87	Hyperimmunoglobulin D syndrome in an Indian family undiagnosed for 11 years. International Journal of Rheumatic Diseases, 2017, 20, 2236-2237.	1.9	2
88	Standard Oral Melphalan Chemotherapy for AL Amyloidosis Revisited Using the Serum Free Light Chain Assay.. Blood, 2005, 106, 3495-3495.	1.4	2
89	A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.. Blood, 2012, 120, 2966-2966.	1.4	2
90	The Prognostic Significance of Phenotypically â€˜Normalâ€™ Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma. Blood, 2014, 124, 2073-2073.	1.4	1

#	Article	IF	Citations
91	Complete and Very Good Partial Responses Are Attainable Endpoints in Elderly Patients (>75 years) with AL Amyloidosis and Are Associated with Improved Overall Survival,. Blood, 2011, 118, 3975-3975.	1.4	1
92	Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Therapy in AL Amyloidosis Is Associated with High Clonal Response Rates and Prolonged Progression Free Survival,. Blood, 2011, 118, 3978-3978.	1.4	1
93	Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis. Blood, 2012, 120, 4074-4074.	1.4	1
94	Longterm Outcomes and Improved Renal Function with Autologous Stem Cell Transplantation (ASCT) in Light Chain Deposition Disease (LCDD). Blood, 2014, 124, 1198-1198.	1.4	1
95	The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis. Blood, 2020, 136, 40-40.	1.4	1
96	Panda eyes and heart failure. British Journal of Hospital Medicine (London, England: 2005), 2005, 66, 700-701.	0.5	0
97	054â€ƒAdult Periodic Fevers, Apthous Ulceration, Pharyngitis and Adenitis: A Single-Centre Experience. Rheumatology, 2016, , .	1.9	0
98	3â€…Treatment response in cardiac al amyloidosis assessed by CMR: findings at 3 months, 6 months and 1 year post-chemotherapy. , 2018, , .		0
99	AB0901â€…TWO TYPES OF SYSTEMIC AMYLOIDOSIS IN A SINGLE PATIENT. , 2019, , .		0
100	19â€…Myocardial perfusion mapping in cardiac amyloidosis- unearthing the spectrum from infiltration to ischaemia. , 2019, , .		0
101	21â€…Intracardiac thrombi in cardiac amyloidosis, a common finding. , 2019, , .		0
102	Impact of Chromosomal Abnormalities Revealed by Interphase FISH on Survival in Primary Light Chain Amyloidosis.. Blood, 2004, 104, 4875-4875.	1.4	0
103	Early Detection of Cardiac Systolic Functional Impairment and Correlation with NT-ProBNP Change in AL Amyloidosis by Cardiac Lateral Wall Tissue Doppler S Wave.. Blood, 2009, 114, 2814-2814.	1.4	0
104	Is There a Role for Thalidomide Maintenance in the Treatment of AL Amyloidosis?.. Blood, 2009, 114, 1863-1863.	1.4	0
105	Remarkable Efficacy of IL-1 Receptor Antagonist In Schnitzler's Syndrome: a Series of 6 Cases. Blood, 2010, 116, 3958-3958.	1.4	0
106	Continuous Therapy with Lenalidomide Correlates with Improved Progression Free Survival in Heavily Pre-Treated Patients with AL Amyloidosis.. Blood, 2012, 120, 2978-2978.	1.4	0
107	A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with Systemic AL Amyloidosis. Blood, 2014, 124, 305-305.	1.4	0